Indication

In combination with bevacizumab for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

Medicine details

Medicine name:
atezolizumab (Tecentriq)
SMC ID:
SMC2349
Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
12 July 2021
SMC meeting date:
01 June 2021
Patient group submission deadline:
05 April 2021